Staidson Biopharmaceuticals Co. Ltd. is testing a combination of two monoclonal antibodies (MAb), STSA-1002 and STSA-1005, in China for the potential treatment of people with severe-to-critical COVID-19.
Growing the international competitiveness of Taiwan’s biotech sector is one of six key strategies Taiwan’s government is heavily invested in, Taiwan President Tsai Ing-wen told attendees via video during the recent BIO Asia-Taiwan conference in Taipei.
Everest Medicines Ltd. has inked an agreement with Gilead Sciences Inc. to pass the latter’s subsidiary, Immunomedics Inc., exclusive rights to develop and commercialize Trodelvy (sacituzumab govitecan) in greater China, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia.
A subsidiary of Jiangxi Jemincare Group Co. Ltd. has out-licensed global rights to its androgen receptor degrader JMKX-002992 to Roche Holding AG and its subsidiary Genentech Inc. in a deal worth up to $650 million.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Astrazeneca, Cullgen, Daewoong, Daiichi Sankyo, Eucure, Everest Medicines, Immvira, Innocare, Moderna, Novavax, SK, Tracon.
Paradigm Biopharmaceuticals Ltd. announced a AU$66 million (US$46.39 million) capital raise to fund its phase III pivotal trial for injectable Zilosul (pentosan polysulfate) to treat osteoarthritis of the knee.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Bioduro-Sundia, Ceapro, GSK, Hemoshear, Intron, Merck, Starpharma, Takeda, Tetra, Vir, X-Chem, Zai Lab.
RSS
